Procept BioRobotics' (PRCT) estimate of its addressable market "is overly exaggerated," Spruce Point Capital Management said in a short report Thursday.
Spruce Point also said the company's claim that it will fundamentally change current benign prostatic hyperplasia protocols is "unrealistic, since there is no one-size-fits-all BPH treatment."
Procept BioRobotics didn't immediately respond to a request for comment from MT Newswires.
The company's shares were down 0.9% in recent trading.
Price: 77.64, Change: -0.67, Percent Change: -0.86
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。